Stem cells used to successfully treat spinal cord injuries in rats

9 April 2006

A study which appears in the March 29 issue of the Journal of Neuroscience suggests that stem cells can repair damaged spinal tissue and help restore function in rats with spinal injuries. The work was carried out by Michael Fehlings and colleagues at the Toronto Western Research Institute and the University of Toronto in Canada.

The group transplanted fluorescently-labeled cells from the brains of adult mice into rats with spinal damage, where the cells were maintained with the addition of growth factors and immunosuppression. In total, one third of the transplanted cells migrated to the site of the spinal injury and were incorporated into the damaged tissue. Over time, these cells developed into the type of cells damaged in the injury, eventually beginning to produce myelin which is vital for nerve fiber signal transduction. The researchers hope that their findings may lead to the development of new treatment approaches in humans.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight